|
|
 |
|
Viewing report
|
|
|
|
US Neuropathic Pain 2008 - 4th Edition: Market Potential Through 2018
WWMR, Sep 2008, Pages: 151
I. EXECUTIVE SUMMARY
II. INTRODUCTION AND METHODOLOGY
III. PHYSIOLOGY OF PAIN
A. Definition of Neuropathic Pain
1. Nerve injury
2. Long duration
3. Abnormal sensations
4. Aggravation by physiological processes
5. Cellular mechanisms of neuropathic pain
B. Definition of Neuropathic Pain States
1. Neuropathic low back pain
2. Diabetic neuropathy
3. Complex regional pain syndrome (CRPS)
4. Peripheral neuropathy in HIV/AIDS
5. Post-herpetic neuralgia
6. Phantom limb pain
7. Spinal cord injury
8. Trigeminal neuralgia (tic douloureux)
9. Cancer Pain
10. Fibromyalgia
IV. CLINICAL ASSESSMENT OF NEUROPATHIC PAIN
1. Qualitative description of pain
2. Standard quantitative pain measurement scales
3. Physical examination of the neuropathic pain patient
V. EPIDEMIOLOGY - CURRENT AND FUTURE
A. Neuropathic Low-Back Pain
1. Low-back pain
2. Low-back pain incidence and prevalence
3. Chronic low-back pain prevalence
4. Neuropathic, chronic low-back pain prevalence
5. Basis of target population
6. US neuropathic, chronic low-back pain population forecasts
B. Diabetic Neuropathy
1. Diabetic neuropathy
2. Diabetes prevalence
3. Diabetic neuropathy prevalence
4. Painful diabetic neuropathy prevalence
5. Moderate-to-severe diabetic neuropathic pain prevalence
6. Chronic moderate-to-severe diabetic neuropathic pain prevalence
7. Basis of target population forecasts
8. US diabetic neuropathy population forecasts
C. Complex Regional Pain Syndrome
1. Complex regional pain syndrome
2. Complex regional pain syndrome prevalence
3. Complex regional pain syndrome severity
4. Basis of target population estimation
5. US CRPS population forecasts
D. HIV/AIDS Neuropathic Pain
1. HIV/AIDS pain
2. AIDS incidence and prevalence
3. HIV (not AIDS) prevalence
4. HIV/AIDS pain prevalence
5. HIV/AIDS neuropathic pain prevalence
6. Basis of target population forecasts
7. US HIV/AIDS neuropathy population forecasts
E. Post-Herpetic Neuralgia
1. Post-herpetic neuralgia
2. Herpes zoster incidence
3. Post-herpetic neuralgia incidence
4. Incidence of persistent post-herpetic neuralgia
5. Persistent post-herpetic neuralgia prevalence
6. Basis of target population forecasts
7. US post-herpetic neuralgia population forecasts
F. Phantom Limb Pain
1. Phantom limb pain
2. Amputation incidence and prevalence
3. Phantom limb pain incidence and prevalence
4. Basis of target population estimation
5. US phantom limb pain population forecasts
G. Spinal Cord Injury
1. Spinal cord injury
2. Spinal cord injury incidence
3. Spinal cord injury prevalence
4. Spinal cord injury chronic pain prevalence
5. Basis of target population estimation
6. US spinal cord injury population forecasts
H. Trigeminal Neuralgia
1. Trigeminal neuralgia
2. Trigeminal neuralgia incidence and prevalence
3. Basis for target population
4. US trigeminal neuralgia population forecasts
I. Neuropathic Cancer Pain
1. Cancer pain
2. Incidence of cancer
3. Incidence of neuropathic cancer pain
4. Prevalence of neuropathic cancer pain
5. Basis for target population
6. US Neuropathic cancer pain population forecasts
J. Fibromyalgia
1. Fibromyalgia
2. Incidence of fibromyalgia
3. Prevalence of fibromyalgia
4. Diagnosed and treated population
5. Basis for target population
6. US fibromyalgia population forecasts
VI. APPROACHES TO TREATMENT OF NEUROPATHIC PAIN
A. Actual Clinical Practice
1. Antidepressants
2. Anticonvulsants
3. Local anesthetics, regional nerve blocks, and sympathetic nerve blocks
4. Antiarrhythmics
5. Non-narcotic synthetic opioids
6. Opioids and semi-synthetic narcotics
7. Muscle relaxants
8. NMDA receptor antagonists
9. Steroids
10. VR-1 receptor agonists
11. Non-steroidal anti-inflammatory agents (NSAIDs)
12. Non-pharmacologic treatments
B. Clinical Practice Guidelines
C. Limitations of Current Treatment
D. Promising New Approaches
E. Future Trends
F. Drugs in Clinical Development to Treat Neuropathic Pain
1. Recent launches/approvals
2. Current pipeline
2.1 Phase III, Preregistration, and Registration
2.2 Phase II
2.3 Phase I
2.4 Discontinued or suspended drugs
2.5 Marketed agents with significant off-label usage for NP
VII. MARKET FORECASTS AND ESTIMATES, CURRENT AND FUTURE
A. Current Sales of Pharmaceutical Products, By Drug Class and Condition
1. 2008 US market: summary by drug class
1.1 Anticonvulsants
1.2 Oral opioids
1.3 Antidepressants
1.4 Other drug classes
2. 2008 US market: summary by neuropathic pain condition
2.1 Fibromyalgia
2.2 Neuropathic back pain
2.3 Diabetic neuropathy (DN)
2.4 Neuropathic cancer pain
2.5 Post-herpetic neuralgia (PHN)
2.6 Complex regional pain syndrome (CRPS)
2.7 Trigeminal neuralgia (TN)
2.8 Phantom limb pain
2.9 HIV/AIDS neuropathic pain
2.10 Spinal cord injury Methodology
B. Market Forecast for Neuropathic Pain
Customers who bought this item also bought
Peripheral Neuropathy and Neuropathic Pain
Neuropathic Pain: Treatments and Prescribing Practices - A Global Survey 2009
Pipeline Insight: Neuropathic Pain - Emerging Drugs Fail to Capitalize in Lucrative Market
Pain Therapeutics - Drugs, Markets and Companies
Disease and Therapy Review: Neuropathic Pain
U.S. Neuropathic Pain Medications Markets
Pipeline Insight: Neuropathic Pain - Pipeline Drugs Fail To Nail Neuropathic Pain
Back Pain Report 2008
Neuropathic Pain Insight - Life Beyond Gabapentin
Strategic Perspectives 2001: Neuropathic pain - Catch 22: high revenue potential but a high risk investment
US Cancer Pain Report
Pain Management - Global Strategic Business Report
|
|
|
|
